Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update. Shandong Xinhua Pharmaceutical ...

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies for kidney diseases, unveiled its financial results for the quarter ending September 30, 2024.

“If approved, we believe OLC’s high potency and low pill burden would provide a best-in-class option for patients with ...

Karnataka: Shilpa Medicare CDMO partner Unicycive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ...

Unicycive has entered into a long term manufacturing contract with Shilpa Medicare for the supply of the product at commercial scale once approved by the USFDA. With Unicycive's NDA now under review, ...

Experts emphasize the importance of certain fruits like watermelon, lemons, berries, cranberries, pineapple, apples, oranges, and grapes in maintaining kidney health. These fruits are rich in ...

Acute and chronic conditions typically differ in how they develop and how long they last. Broadly speaking, acute conditions occur suddenly, have immediate or rapidly developing symptoms, and are ...

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for ...

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease (CKD) on dialysis. “We are thrilled with the FDA ...